Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide effects on intracranial blood flow in T2D
NCT05780905Phase 4Recruiting
- Sponsor
- University of Washington
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by University of Washington. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05780905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780905.